摘要
目的对国产氯雷他定口腔崩解片和进口普通片进行生物等效性研究。方法20名健康男性志愿者按2×2交叉试验方案设计,分别口服受试制剂和参比制剂各20mg,并采集36h内动态血标本;采用HPLC/MS测定血浆中氯雷他定浓度,计算药动学参数,并判定两种制剂是否生物等效。结果受试制剂和参比制剂的主要药动学参数ρmax分别为(19·57±11·09)和(18·97±10·76)μg·L-1,tmax分别为(0·8±0·2)和(0·8±0·2)h,AUC0-36分别为(44·9±17·6)和(42·9±14·6)μg·h·L-1,AUC0-∞分别为(52·6±24·2)和(50·2±19·6)μg·h·L-1,t1/2(ke)分别为(13·1±6·3)和(13·9±6·8)h,两制剂主要药动学参数经对数转换后进行方差分析及双单侧t检验,并计算90%置信区间,表明两种制剂生物等效,受试制剂的人体生物利用度为(103·2±9·0)%。结论两种制剂生物等效。
OBJECTIVE To study the bioequivalence of loratadine orally disintegrating tablets in Chinese healthy volunteers, METI-IOI)S Test preparation(20 mg) and reference preparation(20 mg) were given to 20 male healthy volunteers in randomized two-way crossover design for the pharmacokinetic and relative bioavailability study. Plasma concentrations of loratadine were determined by HPLC/MS. RESULTS The main pharmacokinetic parameters of the two preparations were as follows:ρmax ( 19. 57 ± 11. 09) and (18.97 ±10.76)μg·L^-1,tmax(0.8 ±0.2) and (0.8±0.2)h,AUC0-36(44.9 ±17.6) and (42.9 ±14.6)μg·h·L^-1,AUC0-∞ (52. 6 ± 24. 2) and ( 50. 2 ± 19. 6) μg·h·L^-1, t1/2(ke) ( 13. 1 ± 6. 3 ) and ( 13.9 ±6. 8 ) h, respectively. The mean relative bioavailability of test preparation vs reference preparation were ( 103.2 ± 9. 0 ) %. CONCLUSION The statistical analysis shows the two preparations are bioequivalent.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2007年第2期139-142,共4页
Chinese Pharmaceutical Journal